1. Hybrid-Nanoengineering™
Opportunity
To beat Multi Billion Dollar
Patent Cliff Using A New
Patented Technology
Hybrid-Nanoengineering™
Concept to Bench to Clinic and
More…….
Dr. Mewa Singh
609-902-7128
mewasinghsandhu@hotmail.com

2. Simple to collaborate
• Since I know it is very hard for big pharmaceutical
to review and come up with a decision for
collaboration, so we have a very simple risk free
process at our end. We offer a free of cost one
drug proof-of-concept for our technology. Either
you select a drug from our list of solubility
resolved drugs or you provide us with your drug
to resolve the solubility issue using our Hybrid
Nanoengineering platform.
• We will just take three weeks to inform you
results.

3. What is new
• New concept and new approach
• There have never been used two active molecule in
nanomedicines
• There have never been developed a hybrid nanomedicine
• There have never been used an active molecule to
developed a water soluble drug formulation
• Two water insoluble drugs have never been used to
developed a water soluble formulation, at least without
changing the chemistry
• Chemistry of individual drugs remains unchanged
• IT IS NOT JUST SOLUBILITY BUT A BETTER
TREATMENT

4. What has been accomplished
or we have in our basket
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Drugs List (Resolved solubility problem)
5-aminosalicylic acid
Aspirin
Artemisinin
Aripiprazole, 99%
Azacitidine (Vidaza)
Azathioprine
Bexarotene, Free Acid (4)
Budesonide, 98%
Camptothecin
Capecitabine
Carbenicillin disodium salt
Celecoxib
Cisplatin
Clopidogrel Sulfate
Combrestastatin A4
Curcumin (2cc.) for injection
Cyclosporin A
Daunorubicin hydrochloride
Dexamethasone
Dihydroergotamine Mesylate
Digooxin
Docetaxel
Epothilone A
Erlotinib Monohydrochloride
β-Estradiol
Fexofenadine hcl
Griseofulvin
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Ibuprofen
Itraconazole
Ivermectin
Lenalidomide
Leucovorin Calcium
Loperamide HCL
Loratadine
Magestrol Acetate
Methotrexate
Mevastatin, Minimum 95% HPLC
Nystatin mycostatin
Nimodipine
Ofloxacin
Olanzapine
Paclitaxel from Taxus Brevifolia
Paliperidone
Pomalidomide
Pravastatin Sodium (2)
Prednisone
Quinine
Rapamycin
Resveratrol
Retinonic acid 97%
Rifampin
Rlaxifene hcl
Statine
Sidenafil Citrate >99%
Sulfasalazine
Tadalafil (Cialis) (2)
•
•
•
•
•
•
•
Telaprevir
Thalidomide
Valsartan 99%
Vardenafil hydrocholoride trihydrate
Variconazole
Zidovudine
Ziprasidone hydrocholoride
1. Provisional patent filed in
May, 2012 and final is on its
way this year.
2. There is no common
solubility which cover 63
drugs using one procedure.
3.A simple and inexpensive
technology to resolve
solubility problem of 63 drugs
should deserve some respect.

5. Practical progress
• 86 drugs have tested at lab. scale
• Five drugs have been tested at pilot scale
production
• Three drugs have been tested in dogs
• Two drugs have been tested in dogs and
humans.
The technology is not at early stages of
proof of concept or R&D

6. Technology
• Typical existing nanotechnology involved the
use of phosphophilipids, detergents,
surfactants, polymers and copolymers,
PEGylation and other multistep procedures to
manufacture a nanomedicine.
• We have discovered a new system and a new
molecules to manufacture nanomedicines or to
generate nano-particles.

7. New System and Molecule for
NanoTechnology
• The new molecule discovered is drug that has
its own mode of action to treat the disease.
• The new molecule has its own properties to be
a part of the process to make nanoparticles
• This new molecule of discovery is the
integral part of the whole formulation or
nanomedicine (Hybrid-Nanoengineering™)

8. Experimetal results-1 ( Paclitaxel)
Microscopy
Paclitaxel in water
Paclitaxel in water
Using Hybrid nanoengineering

9. Experimental Results-2
Solubility in water
Paclitaxel in water
Paclitaxel in water
Using Hybrid nanoengineering

10. Passive Targeting
Longer circulation by evading
scavenging by the mononuclear
phagocytic system
And
Bypassing inter-endothelial cells
600-800 nm
Size
Charge
Hydrophobicity
Enhanced Permeability
and Retention (EPR) Effect

11. Experimental reuslts-4 (POTENCY)
10000000
8000000
6000000
4000000
2000000
0
Plate 1
Concentration (µg)
0.015625
0.03125
0.0625
0.125
0.25
1
P average
0.5
Live Cells
MewTaxel is Potent at 1.1 nM ( ic50 is 30nM)
MewTaxel is potent at 5nm ( ic50 is >60nM)
Much lower than taxol

12. Experimental Results-5
• In Mewtaxol ( Paclitaxel) Hypothesis is that
our Hybrid partner shut down the pumps ,
hence incremental in drug concentration leads
to overcome the drug resistance.
• Our Mewtaxol demonstrate the above
mentioned mechanism by killing the paclitaxel
drug resistance cell lines.

13. Mechanism of action
For our Cancer Hybrid formulations
• Control inflammation
• ABCG2 control
• While keeping the parent drug unaltered

14. Overall Summary
• Taxanes are a key first-line component of BC therapy
• The majority of patients treated with a taxane develop
resistance
• To date, most therapies developed to overcome
resistance are inadequate
• Epothilones have shown activity against taxaneresistant tumors
– Poor substrates for P-gp
– May be unaffected by taxane-resistant tubulin mutations
– Positive results in clinical trials

15. Limitations of Conventional,
Solvent-based Taxane Therapy
• Taxanes, like many cancer drugs, are
hydrophobic and require solvents
• Solvents cause hypersensitivity reactions that
necessitate
– Corticosteroid premedication
– Prolonged infusion
• Solvents leach plasticizers, requiring specialized
IV tubing
• Solvents alter the bioavailability of the active
drug
van Zuylen L, et al. Invest New Drugs. 2001;19:125-141; van Tellingen O, et al. Clin Cancer Res. 1999;5:2918-2924; Ellis AG, et al. Cancer
Chemother Pharmacol. 1996;38:81-87; LoRusso PM, Pilat MJ. ONS News. 2004;19:75-76.

16. Alternative Approaches to
Taxane Drug Development
Strategy
Example
Stage
Reference
HAS-Paclitaxel
Pre-clinical
Dosio (2001)
Emulsions
Tocosol paclitaxel
Clinical (Phase III)
Spigel (2002)
Liposomes
LEP-ETU
Clinical (Phase I/II)
Soepenberg
(2004)
Cyclodextrins
PTX-CYD
Pre-clinical
Alcaro (2002)
Nanoparticles
nab-paclitaxel
Approved
Gradishar (2005)
Microspheres
Paclimer
Clinical (Phase I)
Armstrong (2006)
Analogs
BMS-184476; RPR 109881
Clinical (Phase II)
Hildago (2001)
Prodrugs
DHA-Paclitaxel
Clinical (Phase II)
Harries (2004)
Prodrugs
Paclitaxel polyglumex
Clinical (Phase III)
Albain (2006)
Paclitaxel + cyclosporine
Clinical (Phase II)
Kruijtzer (2002)
Pharmaceutical
Co-solvents
Chemical
Biological
Oral
administration
Adapted from ten Tije AJ, et al. Clin Pharmacokinet. 2003;42:665-685.
There is no reported technology like our’s Hybrid-Nanoengineering™

17. Properties
For
Business
Success
Hybrid Nanoengineering™
One Platform fit
for more than
80 Drugs
No
No
Platform
Patent
Protection
Simplicity
and
Cost of
production
No
No
No need to change any
Existing manufacturing
Setup For Generic or new Drug
Need facility change
Simplicity
Synergistic
Or
Potentiating
Of Material used
No
No
No
No
No
No
?
?
Yes
Just filed in 2013
Old Technology
?
Fit for 87 Drugs
List is Growing
?
?
A new way to make use of Nanomedicine
One step
POC in 3-weeks
POC for your Drug
Free

18. Nanotechnology
Hybrid-Nanoengineering™
10-200nm

19. Parameters

20. Time to discover More
• Nanotechnology is used for pharmaceutical
products since many years
• It has solved many problems
• It will solve even more problems in the future:
mainly solubility and bioavailability
• Hybrid-Nanoengineering™ is the newest
invention in Nanotechnology. We need you
join us

21. Nanomedicine
~200 Companies are involved in nanomedicine R&D
• ~40 Nanomedicine products registered
•
–
Active US clinical trials using nano-based drug delivery
systems in september 2009
Emulsion 127
Liposomes 392
Micelle 5
Microemulsion 44
Hybrid-Nanoengineering™
Nanoemulsion 1
2013 IND
Nanoparticle 73
Nanocrystal 8
Nanosuspension 1
(www.clinicaltrials.gov)
–
–
–
–
–
–
–
–

22. To Beat Generic And Patent Cliff
• An inventory of 67 drugs covered by our
patent
• These drugs covered multi billion dollar
market
• Using our technology ,we can avoid the metoo concept in generic market
• Using our technology ,we can beat the
competition.

23. Example:
1.Lipitor
Cholesterol fighter Lipitor held the title "best-selling drug" for a few years, and had been a major source of income for the world's biggest drug company, Pfizer.
Lipitor (atorvastatin) was released in 1998, and by 2006 it had reached worldwide peak sales of $12.9 billion, accounting for 27% of the company's revenue.
In 2010, with $10.8 billion in sales, Lipitor still accounted for 15.8% of Pfizer’s total revenue. Unfortunately, Lipitor lost its patent protection and cut Pfizer's total
net income by 50%. Pfizer's CEO Ian Read stated on January 31, 2012, in USA TODAY: "Patent losses cost the company 5 Billion Dollars."
2.Paclitaxel and Docetaxel
The cumulative sales of paclitaxel have exceeded $ 20 billion so far since 1992. It is estimated that its total global sales were approximately $ 4.5 billion last
year.
Docetaxel is considered the largest oncology product ever developed with global market value at $3 billion in 2009.
Patent and generic cliff can be taken care with our technology.
Hybrid Nanoengineering™ can rejuvenate ageing pharmaceutical assets to counteract generic threats and preserve market share and income streams—it
could become one of the more successful specialty pharmaceutical companies in memory.
Pharmaceutical companies desperately need to protect their revenue streams especially towards the end of their patent life as this is when their products are
most profitable. For that reason, upfront and milestone payments should be significant and commensurate to the perceived value brought to the project by
adopting Hybrid Nanoengineering™ technology.
In addition to milestone payments, royalties would continue for the life of the newly patented product. For drug delivery companies, royalty rates are generally
accepted to be in the 7% to 12% range depending on the time and expense of adopting the extended release mechanism.
Crown’s Strong patent estate and low development costs for new formulations appears to provide for the least expensive and expedient method for preserving
patents and revenue streams.
We see a long term share price in the 30.00 to 40.00 range. Strong Buy.
Mewa Singh, PhD, Meda Biotech, measinghsandhu@hotmail.com, 609-902-7128,
www.nanomeda.com

24. Nano Companies
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Abraxis (USA)
The company's nab™ drug delivery technology uses albumin nanoparticles to deliver drugs into tumors.
Access Pharmaceuticals (USA)
Access' lead anticancer program is ProLindac™ applies the principals of nanoparticulate prodrugs to enhance the delivery of a platinum drug to tumors.
AcryMed (USA)
Manufacturer of SilvaGard, a silver nanoparticle antimicrobial surface treatment for medical devices.
ActiVery (Spain)
The basic technology platform of Activery™ is a nanoparticle production method using supercritical fluids (SCF). Based on SCF the company intends to create new medicines and modified active ingredients for pharmaceutical and cosmetic use.
Acusphere (USA)
The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that
the drug can more rapidly dissolve in water.
AparnaBio (USA)
The company develops biomedical nanoparticle technology and products for research and treatment of human disease. They are developing NanoElectroPlex™, a proprietary tissue selective nanoparticle platform technology based on biodegradable
macromolecular carriers.
Aphios (USA)
The company has developed enabling nanotechnologies for the production of protein nanoparticles, polymer nanospheres and phospholipid nanosomes for the enhanced delivery of drugs
Aquanova (Germany)
Develops and manufactures micelle-like nanoparticulate encapsulation technology for applications in food, cosmetics, pharmaceuticals and biotechnology.
Asklepios BioPharmaceuticals (USA)
A biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles.
Azaya Therapeutics (USA)
A specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Liposomes nanotechnology platform addresses the significant problems associated with delivery of water insoluble drugs.
BIND Biosciences (USA)
BIND Biosciences, Inc. is a biopharmaceutical company developing therapeutic targeted nanoparticles.
Bio Delivery Sciences International (USA)
The company's he Bioral® drug delivery technology encapsulates the selected drug in a nanocrystalline structure termed a "cochleate" cylinder.
BioAlliance Pharma (France)
Manufactures a nanoparticle-based drug delivery platform.
BioCure (USA)
Develops amphiphilic self-assembling nanocapsules and planar membranes for drug delivery.
Bionostra (Spain)
The company's technology is based on the large scale production of nanometric particles known as VLPs (virus like particles). The most advanced application of this technology is the production of viral vector derived vaccines for human and animal
health.
Biophan Technologies (USA)
Develops nanotechnology drug delivery systems based on novel nanomaterials that provide precise control over location and timing of drug delivery.
Biosante Pharmaceuticals (USA)
The company is developing its proprietary calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.
BioSpectrum (South Korea)
A life sciences R&D company with a special focus on skin cell biology. The company has established proprietary technologies for nano-liposomal formulation techniques.

25. Nano companies
•
•
•
•
•
•
•
•
Capsulution (Germany)
Develops nanotechnology-based advanced drug delivery carriers, medical devices and diagnostic particles.
Celator Pharmaceuticals (USA)
The company develops new treatments for cancer based on a portfolio of delivery technologies including liposomes, polymers and nanotechnologies.
Cornerstone Pharmaceuticals (USA)
Develops the Emulsiphan™ nanoparticle tumor targeting technology.
Dabur Pharma (India)
One of the company's delivery systems in the most advanced stages of clinical development is a novel drug delivery system for Paclitaxel. Because of the better safety and pharmacokinetic profile, the polymeric
nanoparticle delivery system is seen as a potential super generic.
•
•
•
•
Debiopharm Group (Switzerland)
Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates.
Delpor (USA)
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device
for the sustained release of therapeutic agents.
•
•
•
•
dermaCM (USA)
The company's NLP technology produces a generation of particles which retains the strength of the Dermazone Solutions' (SDMC) technologies, but includes the ability to produce particles of 60 nanometers to
150 nanometers which are optically clear. The use of this generation of lipid-based particle delivery system provides the ability to control the size of the final particle by controlling the number of NLPs used to
assemble the finished particle. This system maintains very high loading capacity of passenger molecules and uses only safe, all natural ingredients to form both the NLPs and the final delivery system.
Dune Sciences (USA)
Dune Sciences is an emerging technology company specializing in products and services that will facilitate the development and commercialization of nano-enabled products. The company employs several
patented and patent-pending technologies to engineer interfaces for the integration of new materials and devices in medicine, bionanotechnology, energy technologies, and nanoscience.
•
•
•
•
•
•
•
•
•
•
Elan (Ireland)
The company's proprietary NanoCrystal® technology can enable formulation and improve compound activity and final product characteristics for poorly water-soluble compounds.
Endor Nanotechnologies (Spain)
The company's mission is to develop and license R&D projects in Nanotechnology applied to Life Sciences. Endor is also developing pioneer in-house projects in novel Nanomaterials.
Eqalix (USA)
The company is in the Regenerative Medicine space. The backbone of Eqalix's technology resides in development of a plant-based protein nanofiber structure.
Eugene Science (South Korea)
Develops food additives with specially formulated nanoparticles which improve bioavailability.
Exilica (UK)
The company develops unique molecular delivery systems. Its spherical micrometer sizes polymer particles act like micro sponges and absorb molecules while the sub-micrometer sized Hollow silica shells have an
internal void space and act much like a standard container.

26. Nano Companies
•
•
GeneSegues (USA)
The company's targeted nanocapsule technology is designed using a flexible formulation process and can carry large or small molecules, custom target delivery to different organs,
tissues and cells, and be applied several ways including topically, intravenously, or via devices or tablets.
•
•
•
•
iCeutica (USA)
iCeutica has developed the Encapsulated Organic Nanoparticles (EON™) Platform to produce consistent nano-sized drug particles.
Intezyn Technologies (USA)
The foundation of the company's IVEC™ drug delivery platform is based on polymer micelle technology, spherical nanosized capsules formed by the assembly of block copolymers in
water.
•
•
•
•
Introgen Therapeutics (USA)
Develops and markets a nanoparticle vector technology that combines DNA with the lipids DOTAP and cholesterol to create a synthetic gene delivery vehicle.
Keystone Nano (USA)
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots
(MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
•
•
•
•
Labopharm (Canada)
Develops novel polymeric, nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs.
LiPlasome Pharma (Denmark)
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive
and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
•
•
Lipoxen (UK)
Lipoxen is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anticancer drugs.
•
•
Lumera (USA)
Develops proprietary nanoengineered polymer materials and products based on these materials for a broad range of applications.

27. Nano Companies
•
•
•
•
Magforce Nanotechnologies (Germany)
Provides integrated systems for nanotechnology-based cancer therapy
Mersana Therapeutics (USA)
The company utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical
properties.
•
•
•
•
•
•
•
•
•
•
•
•
Midatech Group (UK)
Design, synthesis and manufacture of biocompatible nanoparticles called nanocells.
NanoBio Corporation (USA)
A biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines, based on its nanotechnology platform.
Nanocarrier (Japan)
Applies the manufacturing technology of ultrafine particles termed 'micellar nanoparticles' to use them as carriers for drugs, such as anticancer agents.
NanoMedica (USA)
The company's core technology includes a suite of proprietary drug discovery and drug delivery tools referred to as the NanoDiscovery™ platform.
Nanospectra Biosciences (USA)
Develops a therapeutic medical device which incorporates a new class of microparticles/nano-shells to selectively destroy solid tumors.
Nanotherapeutics (USA)
Uses nanotechnology to create novel drug delivery systems.

28. Nano companies
•
•
•
•
Oasmia (Sweden)
Oasmia Pharmaceutical AB develops next generation cancer drugs based on nanotechnology for human and veterinary use.
Particle Sciences (USA)
Particle Sciences is an integrated provider of both standard and nanotechnology approaches to drug development and delivery. The company originally pioneered use of encapsulated ingredients and
nanoparticles for sunscreens and personal care. In 1999 the company licensed a portion of its nanotechnology portfolio to BASF and focused its efforts on providing services to Life Sciences companies. Now,
through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution designed to minimize the time
and risk between discovery and the clinic.
•
•
PDS Biotechnology (USA)
PDS Biotechnology Corporation is a biopharmaceutical company applying the company's platform Versamune nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the
treatment of cancer and infectious diseases.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
PharmaIN (USA)
Develops a Protected Graft Copolymer (PGC™) nano-carrier drug delivery system.
PharmaNova (USA)
PharmaNova Inc. is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using our proprietary nanoparticle technology platform and other
complementary formulation and drug delivery technologies.
orthopaedics markets.
PolyMicrospheres (USA)
The company is specialized in developing cutting-edge nanoparticle technologies for the development of targeted drug delivery systems.
pSivida (Australia)
A nanobiotechnology company developing commercializing drug delivery products and new nanostructured biomaterials.
Rexahn Pharmaceuticals (USA)
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of
anticancer drugs.
Starpharma (Australia)
Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology products for pharmaceutical, life-science and other applications.
Tempo Pharmaceuticals (USA)
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop
multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
•
•
Uluru (USA)
Developed and manufactures a novel, biomaterial which utilizes hydrogel nanoparticles which aggregate to form a material of varying strength and elasticity which has extensive medical application including
wound management and burn care, tissue regeneration and drug delivery devices.

29. www.nanomeda.com
• None of the existing companies has any
technology close to our unique platform.
•
A recent report by Cientifica, a leading global emerging technology consulting firm predicts:
Nanotech-enabled drug delivery therapeutics is set to grow from a current value of $2.3 billion to $136 billion by the year
2021.
Nano
Nano
Nano
Nano
Nano
Nano
Nano
Nano
Nano
Hybrid-Nanoengineering™
Nano
Nano
Nano
Nano
Nano